Literature DB >> 2339792

Measurement of kynurenic acid in mammalian brain extracts and cerebrospinal fluid by high-performance liquid chromatography with fluorometric and coulometric electrode array detection.

K J Swartz1, W R Matson, U MacGarvey, E A Ryan, M F Beal.   

Abstract

Kynurenic acid is a broad-spectrum excitatory amino acid (EAA) receptor antagonist which is present in the mammalian central nervous system. We describe a method for the measurement of kynurenic acid using isocratic reverse-phase high-performance liquid chromatography (HPLC) with fluorometric detection enhanced by Zn2+ as a postcolumn reagent. The method requires no prior sample preparation procedures other than extraction with 0.1 M HClO4. The reliability of the primary fluorometric method was verified by comparing measurements of tissue concentrations of kynurenic acid in human cerebral cortex and putamen using three different methods of separation with fluorometric detection, as well as four methods utilizing HPLC with coulometric electrode array system (CEAS) detection. All seven methods produced comparable results. The concentration of kynurenic acid in human cerebral cortex was 2.07 +/- 0.61 pmol/mg protein, and in human putamen, 3.38 +/- 0.81 pmol/mg protein. Kynurenic acid was also found to be present in human cerebrospinal fluid (CSF) at a concentration of 5.09 +/- 1.04 nM. The regional distribution of kynurenic acid in the rat brain was examined. Kynurenic acid concentrations were highest in brainstem (149.6 fmol/mg protein) and olfactory bulb (103.9 fmol/mg protein) and lowest in thalamus (26.0 fmol/mg protein). There were no significant postmortem changes in kynurenic acid concentrations in cerebral cortex, hippocampus, and striatum at intervals ranging from 0 to 24 h. Perfusion of the cerebral vasculature with normal saline prior to sacrifice did not significantly alter kynurenic acid content in rat hippocampus, cerebral cortex, or striatum. The analytical methods described are the most sensitive (10-30 fmol injection-1) and specific (utilizing both excitation and emissions properties and electrochemical reaction potentials, respectively) methods for determining kynurenic acid in brain tissue extracts and CSF. These methods should prove useful in examining whether kynurenic acid modulates EAA-mediated neurotransmission under physiologic conditions, as well as in determining the role of kynurenic acid in excitotoxic neuronal death.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2339792     DOI: 10.1016/0003-2697(90)90309-w

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  25 in total

1.  Kynurenic acid inhibits the release of the neurotrophic fibroblast growth factor (FGF)-1 and enhances proliferation of glia cells, in vitro.

Authors:  Claudia Di Serio; Andrea Cozzi; Ilaria Angeli; Laura Doria; Isabella Micucci; Silvia Pellerito; Patrizia Mirone; Giulio Masotti; Flavio Moroni; Francesca Tarantini
Journal:  Cell Mol Neurobiol       Date:  2005-09       Impact factor: 5.046

2.  Elevated levels of kynurenic acid in the cerebrospinal fluid of patients with bipolar disorder.

Authors:  Sara K Olsson; Martin Samuelsson; Peter Saetre; Leif Lindström; Erik G Jönsson; Conny Nordin; Göran Engberg; Sophie Erhardt; Mikael Landén
Journal:  J Psychiatry Neurosci       Date:  2010-05       Impact factor: 6.186

3.  Increased levels of IL-6 in the cerebrospinal fluid of patients with chronic schizophrenia--significance for activation of the kynurenine pathway.

Authors:  Lilly Schwieler; Markus K Larsson; Elisabeth Skogh; Magdalena E Kegel; Funda Orhan; Sally Abdelmoaty; Anja Finn; Maria Bhat; Martin Samuelsson; Kristina Lundberg; Marja-Liisa Dahl; Carl Sellgren; Ina Schuppe-Koistinen; Camilla Svensson; Sophie Erhardt; Göran Engberg
Journal:  J Psychiatry Neurosci       Date:  2015-03       Impact factor: 6.186

4.  Kynurenic acid, an endogenous constituent of rheumatoid arthritis synovial fluid, inhibits proliferation of synoviocytes in vitro.

Authors:  Jolanta Parada-Turska; Wojciech Rzeski; Wojciech Zgrajka; Maria Majdan; Martyna Kandefer-Szerszeń; Waldemar Turski
Journal:  Rheumatol Int       Date:  2005-10-12       Impact factor: 2.631

Review 5.  Pharmacological manipulation of kynurenic acid: potential in the treatment of psychiatric disorders.

Authors:  Sophie Erhardt; Sara K Olsson; Göran Engberg
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

6.  Kynurenic acid production in cultured bovine aortic endothelial cells. Homocysteine is a potent inhibitor.

Authors:  Katarzyna Wejksza; Wojciech Rzeski; Jolanta Parada-Turska; Barbara Zdzisinska; Robert Rejdak; Tomasz Kocki; Etsuo Okuno; Martyna Kandefer-Szerszen; Eberhart Zrenner; Waldemar A Turski
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-02-10       Impact factor: 3.000

7.  Kynurenic acid and 5,7-dichlorokynurenic acids improve social and object recognition in male rats.

Authors:  Z Hlinák; I Krejci
Journal:  Psychopharmacology (Berl)       Date:  1995-08       Impact factor: 4.530

8.  Chronic neuroleptic treatment reduces endogenous kynurenic acid levels in rat brain.

Authors:  G Ceresoli-Borroni; A Rassoulpour; H-Q Wu; P Guidetti; R Schwarcz
Journal:  J Neural Transm (Vienna)       Date:  2006-02-09       Impact factor: 3.575

Review 9.  The Kynurenine Pathway in the Acute and Chronic Phases of Cerebral Ischemia.

Authors:  María Isabel Cuartero; Juan de la Parra; Alicia García-Culebras; Iván Ballesteros; Ignacio Lizasoain; María Ángeles Moro
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

10.  Dopamine receptor activation reveals a novel, kynurenate-sensitive component of striatal N-methyl-D-aspartate neurotoxicity.

Authors:  B Poeggeler; A Rassoulpour; H-Q Wu; P Guidetti; R C Roberts; R Schwarcz
Journal:  Neuroscience       Date:  2007-07-16       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.